Navigation Links
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
Date:11/2/2008

Novartis notified of data set closing, Top-line results expected in

November

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic drug. CTI plans to report top-line results in November.

"We are excited to have reached the end of the treatment phase and follow-up period for the pixantrone pivotal study and look forward to reporting top-line results in November," said James A. Bianco, M.D., CEO of Cell Therapeutics. "Complete remissions in this patient population with end stage advanced disease are seldom accomplished with the current standard of care. Pixantrone, if successful in achieving the study objectives, could offer these patients a significant benefit, and we would work with the FDA to submit an NDA in 2009."

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
5. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
6. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
7. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
10. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
11. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...sia-FirstCall/--ChinaSkyOne,Medical,Inc.("ChinaSky...gfullyintegratedpharmaceuticalcompanydevelopingand...icofChina("PRC"),today,announcedthattheCompanyrece...lofPharmaceuticalandBiologicalProducts("ICPBP")exa...rHumanProstateSpecific,Antigen(ColloidalGold)andit...
(Date:11/25/2009)...--AccordingtoMillenniumResearchGroup(MRG),thegloba...enearly$3billionUSmarketfortraumafixationdeviceswi...itetherecenteconomicslowdown.MRG,s USMarketsforTra...inhighlydynamicoverthenextfiveyears,withcompetitor...vedsegmentsofthetraumafixationmarket,fuelingmarket...
(Date:11/25/2009)...URG,November25/PRNewswire/--,iThembaPharmaceutical...hattheyhavesignedacollaborativeagreementtojointlym...lasscomputationalchemistryandleaddiscoveryexpertis...demedicinaland,syntheticchemistrysupporttoprojects....iThembaPharmaceuticalsandPyxisDiscovery,alsoannou...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 1Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 2Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 1Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 2Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 4Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 5Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 6Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 7Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 8Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 9Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 10Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 11TeamStaff Inc To Announce Third Quarter Results 54190 1TeamStaff Inc To Announce Third Quarter Results 54190 2TeamStaff Inc To Announce Third Quarter Results 54190 3
(Date:11/25/2009)...EMERYVILLE,Calif.,Nov.25/PRNewswire-FirstCall/-- ...cedthatthecompanywillhosttwoinvestoreventsinDecemb...:00a.m.CT/10:00a.m.ET ,, Principalinvestigato...ibinrelapsedand/orrefractorymultiplemyeloma,asfeat...lMeetingandExpositioninNewOrleans,LA.Theteleconfer...
(Date:11/25/2009)...LOSANGELES,Nov.25/PRNewswire-USNewswire/--TheBlack...odetermineexecutiveleadershipfor2010. ,, Thenew...cialtiesinpublicpolicy,law,finance,governmenthealt...eBoardalsocomesfromawiderangeofpersonalbackgrounds...melivingwithHIVthemselves,andrepresentingmultiplea...
(Date:11/25/2009)...rtuitous discovery that grew out of a collaboratio...ntially offer hope to the nearly 10 million Americ... , Also known as hardening of the arteries, pe...culatory problem in which narrowed arteries reduce...red a red flag for vascular disease, heart attack ...
(Date:11/25/2009)... forgetfulness could lead mothers to overlook need... 25 (HealthDay News) -- A mother,s depression can ...ound. , Their six-month study of 262 black moth...others had more depressive symptoms had more frequ...h fewer depressive symptoms had less frequent asth...
(Date:11/25/2009)... LittleImprovementShownforthe4thStraightYear ,...day,LungCancerAlliance-Georgia(LCA-GA)issuedthe 4t...smentofprogressbeingmadeagainstthislethaldiseasein...ance(LCA),theonlynationalorganizationdedicatedexcl...ithoratriskforlungcancer. ,, (Logo: http://www....
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...experts reported that women in India are gradually...d they comprise about 40 percent of India’s infect...e susceptible to HIV infection. Besides, gender di...n security unit, United Nations Development Fund f...
...entists have now found that women who skip their m...r methods are less likely to develop cancers// rel...vical cancer, uterine cancer, ovarian cancer. ...varian and endometrial cancers, says Professor Ian...
...ach may have some beneficial effects in fighting c...cancer have the potential to perform better with t...body’s immune system to recognize cancer tissues a...ity College London (UCL) have been able to place a...
... Cancer patients who actively use the internet to ... positive outlook, and are well aware of the possi...ried out by the Temple University and has been pub...eiterated that this is the first study that has so...
... referral management centres have been blamed for ...for surgery. These centres that dictate the where ...between the hospitals and GPs. Officials belonging...s are currently being managed by staff belonging t...
...st plastic surgeons to be greedier! Not satisfied ...splant on a French woman, plastic surgeons are hun...Reporting in the March issue of Plastic and Recons...dure of a full-face transplant. "For the fir...
Other Medicine News:Health News:Biologically Women Are More Vulnerable To HIV Infection 2Health News:Internet Research Fosters Confidence and Positivity in Cancer Patients 2Health News:Referral Schemes Blamed By GPs For Treatment Delay 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: